{"id":1049,"date":"2022-01-12T13:40:07","date_gmt":"2022-01-12T21:40:07","guid":{"rendered":"https:\/\/www.iths.org\/cpci\/?page_id=1049"},"modified":"2022-01-12T13:40:07","modified_gmt":"2022-01-12T21:40:07","slug":"cpci-clinical-trials","status":"publish","type":"page","link":"https:\/\/www.iths.org\/cpci\/activities\/patient-access\/cpci-clinical-trials\/","title":{"rendered":"CPCI Clinical Trials"},"content":{"rendered":"\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Trial Name<\/th>Description<\/th>Sites<\/th>Link<\/th>\n<\/tr>\n<\/thead>\n
alloRESIST<\/td>A Study to Evaluate the Safety, Immunologic, and Virologic RESponses of Donor Derived (DD) HIV-Specific T-cells (HST) With Non-escaped Epitope Targeting (NEETs) in HIV-Infected Individuals on Antiretroviral Therapy Following Allogeneic Bone Marrow Transplantation (alloRESIST)<\/td>
  • Children's National Hospital
    \n<\/ul><\/td>
NCT04248192<\/a><\/td>\n<\/tr>\n
ATLANTIC<\/td>Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts<\/td>
  • Children's National Hospital
    \n<\/ul><\/td>
NCT04691622<\/a><\/td>\n<\/tr>\n
ATTACK<\/td>Phase I Research Study Utilizing Allogeneic Multi Tumor-Associated Antigen-Specific T Lymphocytes to Advance the Care of Patients With High-Risk Solid Tumors<\/td>
  • Children's National Hospital
    \n<\/ul><\/td>
NCT05238792<\/a><\/td>\n<\/tr>\n
BMTCTN1903<\/td>Administration of HIV-specific T Cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue - Auto -RESIST. BMTCTN1903<\/td>
  • Children's National Hospital
    \n<\/ul><\/td>
NCT04975698<\/a><\/td>\n<\/tr>\n
BrainChild-03<\/td>Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma\/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors<\/td>
  • Seattle Children's Hospital
    \n<\/ul><\/td>
NCT04185038<\/a><\/td>\n<\/tr>\n
BrainChild-04<\/td>Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors<\/td>
  • Seattle Children's Hospital<\/ul><\/td>
NCT05768880<\/a><\/td>\n<\/tr>\n
CHEERS<\/td>Adoptive Cord Blood ImmunotHerapy Using Expanded Cord Blood T Cells for EBV, CMV, BKV and Adenovirus Reactivation\/Infection or ProphylaxiS<\/td>
  • Children's National Hospital
    \n<\/ul><\/td>
NCT03594981<\/a><\/td>\n<\/tr>\n
CRISPR_SCD001<\/td>Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease<\/td>
  • UCSF Benioff Children's Hospitals
    \n<\/ul><\/td>
NCT04774536<\/a><\/td>\n<\/tr>\n
EDIT-301<\/td>A Phase 1\/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease<\/td>
  • UCSF Benioff Children's Hospitals
    \n
  • Colorado Children's Hospital
    \n<\/ul><\/td>
NCT04853576<\/a><\/td>\n<\/tr>\n
ENLIGHTen-01<\/td>A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+AML<\/td>
  • Seattle Children's Hospital
    \n<\/ul><\/td>
NCT05105152<\/a>2<\/td>\n<\/tr>\n
HGB 206<\/td>A Phase 1 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease<\/td>
  • UCSF Benioff Children's Hospitals
    \n<\/ul><\/td>
NCT02140554<\/a><\/td>\n<\/tr>\n
MeDCaP<\/td>Mesenchymal Stromal Cells Delivery Through Cardiopulmonary Bypass in Pediatric Cardiac Surgery (MeDCaP)<\/td>
  • Children's National Hospital
    \n<\/ul><\/td>
NCT04236479<\/a><\/td>\n<\/tr>\n
NATS<\/td>Novel Antigens Targeted by ex Vivo Expanded T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation<\/td>
  • Children's National Hospital
    \n<\/ul><\/td>
NCT03180216<\/a><\/td>\n<\/tr>\n
PLAT-07<\/td>A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed\/Refractory Leukemia or Lymphoma<\/td>
  • Children's Hospital Los Angeles
    \n
  • Seattle Children's Hospital
    \n<\/ul><\/td>
NCT04571138<\/a><\/td>\n<\/tr>\n
PLAT-08<\/td>Pediatric And Young Adult Leukemia Adoptive Therapy (PLAT)-08: A Phase 1 Study Of SC-DARIC33 In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML<\/td>
  • Seattle Children's Hospital
    \n<\/ul><\/td>
NCT05105152<\/a><\/td>\n<\/tr>\n
ReMIND<\/td>Phase I REsearch on Multi-antigen T Cell Infusion Against Neuro-oncologic Disease (ReMIND)<\/td>
  • Children's National Hospital
    \n<\/ul><\/td>
NCT03652545<\/a><\/td>\n<\/tr>\n
RESIST<\/td>A Phase I Study to Evaluate the Safety, Immunologic, and Virologic RESponses of HIV-Specific T-cells With Non-Escaped Epitope Targeting (HST-NEETs) as a Therapeutic Strategy in HIV-Infected Individuals on Antiretroviral Therapy During Acute And Chronic Infection <\/td>
  • Children's National Hospital
    \n<\/ul><\/td>
NCT03485963<\/a><\/td>\n<\/tr>\n
RESOLVE<\/td>Multi-institutional Prospective Phase I Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies<\/td>
  • Children's National Hospital
    \n<\/ul><\/td>
NCT02203903<\/a><\/td>\n<\/tr>\n
REST<\/td>Research Study Utilizing Expanded multi-antigen Specific lymphocytes for the treatment of Solid Tumors (REST)<\/td>
  • Children's National Hospital
    \n<\/ul><\/td>
NCT02789228<\/a><\/td>\n<\/tr>\n
STRIvE-01<\/td>Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent\/Refractory Solid Tumors in Children and Young Adults<\/td>
  • Seattle Children's Hospital
    \n<\/ul><\/td>
NCT03618381<\/a><\/td>\n<\/tr>\n
SUSTAIN<\/td>Phase I Study Utilizing Tumor Associated Antigen Specific T cells (TAA-T) with PD1 Inhibitor Nivolumab for Relapsed\/Refractory Lymphoma <\/td>
  • Children's National Hospital
    \n<\/ul><\/td>
NCT03843294<\/a><\/td>\n<\/tr>\n
TDT<\/td>A Phase 1\/2, Open-label, Single-arm\u00a0Study to Assess the Safety, Tolerability, and Efficacy of ST-400\u00a0Autologous Hematopoietic Stem Cell Transplant for\u00a0Treatment of Transfusion-Dependent Beta-thalassemia\u00a0(TDT)<\/td>
  • UCSF Benioff Children's Hospitals
    \n<\/ul><\/td>
NCT03432364<\/a><\/td>\n<\/tr>\n
TONI<\/td>T CELL THERAPY OPPOSING NOVEL COVID-19 INFECTION IN IMMUNOCOMPROMISED PATIENTS<\/td>
  • Children's National Hospital
    \n<\/ul><\/td>
NCT05141058<\/a><\/td>\n<\/tr>\n
UCD19<\/td>Phase I\/II Dose Escalation and Preliminary Efficacy of CD19 Directed CAR-T Cells Generated Using the Miltenyi CliniMACs Prodigy System (UCD19 CAR-T) in Pediatric Patients with Relapsed and\/or Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL)<\/td>
  • Colorado Children's Hospital
    \n<\/ul><\/td>
NCT04544592<\/a><\/td>\n<\/tr>\n
ZUMA-4<\/td>A Phase 1\/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects With Relapsed\/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)<\/td>
  • Children's National Hospital
    \n
  • UCSF Benioff Children's Hospitals
    \n<\/ul><\/td>
\u00a0NCT02625480<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n","protected":false},"excerpt":{"rendered":"Trial NameDescriptionSitesLink alloRESISTA Study to Evaluate the Safety, Immunologic, and Virologic RESponses of Donor Derived (DD) HIV-Specific T-cells (HST) With Non-escaped Epitope Targeting (NEETs) in HIV-Infected Individuals on Antiretroviral Therapy Following Allogeneic Bone Marrow Transplantation (alloRESIST)Children's National Hospital NCT04248192 ATLANTICAdoptive T Lymphocyte Administration for Chronic...","protected":false},"author":84,"featured_media":0,"parent":301,"menu_order":10,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1049","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.iths.org\/cpci\/wp-json\/wp\/v2\/pages\/1049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.iths.org\/cpci\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.iths.org\/cpci\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.iths.org\/cpci\/wp-json\/wp\/v2\/users\/84"}],"replies":[{"embeddable":true,"href":"https:\/\/www.iths.org\/cpci\/wp-json\/wp\/v2\/comments?post=1049"}],"version-history":[{"count":2,"href":"https:\/\/www.iths.org\/cpci\/wp-json\/wp\/v2\/pages\/1049\/revisions"}],"predecessor-version":[{"id":1054,"href":"https:\/\/www.iths.org\/cpci\/wp-json\/wp\/v2\/pages\/1049\/revisions\/1054"}],"up":[{"embeddable":true,"href":"https:\/\/www.iths.org\/cpci\/wp-json\/wp\/v2\/pages\/301"}],"wp:attachment":[{"href":"https:\/\/www.iths.org\/cpci\/wp-json\/wp\/v2\/media?parent=1049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}